• 1
    Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012;12:1926.
  • 2
    Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 2010;24:177881.
  • 3
    Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007;21:17717.
  • 4
    De Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994;331:3416.
  • 5
    Feldblum PJ, Lie CC, Weaver MA, Van Damme L, Halpern V, Adeiga A, et al. Baseline factors associated with incident HIV and STI in four microbicide trials. Sex Transm Dis 2010;37:594601.
  • 6
    Kapiga SH, Lyamuya EF, Lwihula GK, Hunter DJ. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS 1998;12:7584.
  • 7
    Kiddugavu M, Makumbi F, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS 2003;17:23340.
  • 8
    Kleinschmidt I, Rees H, Delany S, Smith D, Dinat N, Nkala B, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception 2007;75:4617.
  • 9
    Kumwenda JJ, Makanani B, Taulo F, Nikhoma C, Kafulafula G, Li Q, et al. Natural history and risk factors associated with early and established HIV type 1 infection among reproductive-age women in Malawi. Clin Infect Dis 2008;46:191320.
  • 10
    Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95102.
  • 11
    Reid SE, Dai JY, Wang J, Sichalwie BN, Akpomiemie G, Cowan FM, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr 2010;53:60613.
  • 12
    Curtis KM, Nanda K, Kapp N. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. AIDS 2009;23 (Suppl 1):S5567.
  • 13
    UNAIDS. Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS, 2010.
  • 14
    WHO. Trends in Maternal Mortality: 1990 to 2008. Geneva, Switzerland: World Health Organization, 2010.
  • 15
    WHO. Unsafe Abortion: Global and Regional Estimates of the Incidence of Unsafe Abortion and Associated Mortality in 2008. Geneva, Switzerland: World Health Organization, 2008.
  • 16
    World Contraceptive Use. 2011 []. Last accessed 18 November 2011.
  • 17
    Guttmacher Institute. Facts on Abortion and Unintended Pregnancy in Africa. New York City, NY: The Guttmacher Institute, 2009.
  • 18
    WHO. Antiretroviral Therapy Coverage Among HIV-Infected Pregnant Women for PMTCT. Geneva, Switzerland: World Health Organization, 2011.
  • 19
    Simoens S. Health economic assessment: a methodological primer. Int J Environ Res Public Health 2009;6:295066.
  • 20
    Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397404.
  • 21
    Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011;CD003510.
  • 22
    Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:81724.
  • 23
    Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011;155:20916.
  • 24
    Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, et al. The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study. J Acquir Immune Defic Syndr 2008;47:93100.